UBS Group
CERE

UBS Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

UBS Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-87,100
Closed -$3.56M – 10434
2024
Q2 		$3.56M Buy
+87,100
New +$3.63M ﹤0.01% 3179
2023
Q1 		– Sell
-50,700
Closed -$1.6M – 10757
2022
Q4 		$1.6M Buy
+50,700
New +$1.43M ﹤0.01% 3608

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

UBS Group's CERE Position: Q3 2024 in Review

UBS Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 291,457 shares — an estimated $11.9M sold.

UBS Group first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $12.9M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • UBS Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 291,457 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $11.9M.
  • UBS Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • UBS Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $12.9M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.